Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

NCT03511222 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03511222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03511222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Terminated
Start date
September 11, 2018
Completion date
May 28, 2020
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, solid tumor